Kowa Research Institute, Inc.

Quick facts

Marketed products

• Darunavir/Ritonavir (Prezista) · Infectious Disease
  Darunavir is an HIV protease inhibitor that blocks the viral protease enzyme, preventing the maturation of HIV particles and reducing viral replication.
• Pitavastatin (NK-104) · Cardiovascular
  Pitavastatin inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis, thereby reducing LDL cholesterol levels.

Phase 3 pipeline

• K-161 · Diabetes
  K-161 is a small molecule that targets the SGLT2 receptor.
• Placebo (for K-877)
  This is a placebo, meaning it has no active therapeutic effect.

Phase 1 pipeline

• C: Pitavastatin IR 8 mg

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Kowa Research Institute, Inc. portfolio CI brief
• Kowa Research Institute, Inc. pipeline updates RSS